KIT (CD117)-Positive Breast Cancers Are Infrequent and Lack KIT Gene Mutations

Gibson P. C., Cooper K. CD117 (KIT): a diverse protein with selective applications in surgical pathology. Adv. Anat. Pathol., 9: 65-69,  2002.

Arber D. A., Tamayo R., Weiss L. M. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum. Pathol., 29: 498-504,  1998.

Lammie A., Drobnjak M., Gerald W., Saad A., Cote R., Cordon-Cardo C. Expression of c-kit and kit ligand proteins in normal human tissues. J. Histochem. Cytochem., 42: 1417-1425,  1994.

Tsuura Y., Hiraki H., Watanabe K., Igarashi S., Shimamura K., Fukuda T., Suzuki T., Seito T. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch., 424: 135-141,  1994.

Natali P. G., Nicotra M. R., Sures I., Santoro E., Bigotti A., Ullrich A. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res., 52: 6139-6143,  1992.

Matsuda R., Takahashi T., Nakamura S., Sekido Y., Nishida K., Seto M., Seito T., Sugiura T., Ariyoshi Y., et al Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am. J. Pathol., 142: 339-346,  1993.

Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U., Talpaz M., Druker B., Goldman J., O’Brien S. G., Russell N., Fischer T., Ottmann O., Cony-Makhoul P., Facon T., Stone R., Miller C., Tallman M., Brown R., Schuster M., Loughran T., Gratwohl A., Mandelli F., Saglio G., Lazzarino M., Russo D., Baccarani M., Morra E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 346: 645-652,  2002.

Miettinen M., Furlong M., Sarlomo-Rikala M., Burke A., Sobin L. H., Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am. J. Surg. Pathol., 25: 1121-1133,  2001.

Sawyers C. L. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. J. Clin. Oncol., 20: 3568-3569,  2002.

Tsuura Y., Suzuki T., Honma K., Sano M. Expression of c-kit protein in proliferative lesions of human breast: sexual difference and close association with phosphotyrosine status. J. Cancer Res. Clin. Oncol., 128: 239-246,  2002.

Chui X., Egami H., Yamashita J., Kurizaki T., Ohmachi H., Yamamoto S., Ogawa M. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br. J. Cancer, 73: 1233-1236,  1996.

Natali P. G., Nicotra M. R., Sures I., Mottolese M., Botti C., Ullrich A. Breast cancer is associated with loss of the c-kit oncogene product. Int. J. Cancer, 52: 713-717,  1992.

Demetri G. D., von Mehren M., Blanke C. D., Van den Abbeele A. D., Eisenberg B., Roberts P. J., Heinrich M. C., Tuveson D. A., Singer S., Janicek M., Fletcher J. A., Silverman S. G., Silberman S. L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B. J., Corless C., Fletcher C. D., Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med., 347: 472-480,  2002.

van Oosterom A. T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., Martens M., Webb A., Sciot R., Van Glabbeke M., Silberman S., Nielsen O. S. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet, 358: 1421-1423,  2001.

Hernandez-Boluda J. C., Cervantes F. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies. Drugs Today (Barc.), 38: 601-613,  2002.

Mace J., Sybil Biermann J., Sondak V., McGinn C., Hayes C., Thomas D., Baker L. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer (Phila.), 95: 2373-2379,  2002.

Dagher R., Cohen M., Williams G., Rothmann M., Gobburu J., Robbie G., Rahman A., Chen G., Staten A., Griebel D., Pazdur R. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res., 8: 3034-3038,  2002.

Ma Y., Zeng S., Metcalfe D. D., Akin C., Dimitrijevic S., Butterfield J. H., McMahon G., Longley B. J. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood, 99: 1741-1744,  2002.

Longley B. J., Reguera M. J., Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk. Res., 25: 571-576,  2001.

Joensuu H., Roberts P. J., Sarlomo-Rikala M., Andersson L. C., Tervahartiala P., Tuveson D., Silberman S., Capdeville R., Dimitrijevic S., Druker B., Demetri G. D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med., 344: 1052-1056,  2001.

Demetri G. D. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin. Oncol., 28: 19-26,  2001.

Joensuu H., Dimitrijevic S. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann. Med., 33: 451-455,  2001.

Verweij J., Judson I., van Oosterom A. STI571: a magic bullet?. Eur. J. Cancer, 37: 1816-1819,  2001.

Allander S. V., Nupponen N. N., Ringner M., Hostetter G., Maher G. W., Goldberger N., Chen Y., Carpten J., Elkahloun A. G., Meltzer P. S. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res., 61: 8624-8628,  2001.

Elston C. W., Ellis I. O. Pathological prognostic factors in breast cancer.The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 1991: 403-410,  1991.

Bubendorf L., Kononen J., Koivisto P., Schraml P., Moch H., Gasser T. C., Willi N., Mihatsch M. J., Sauter G., Kallioniemi O. P. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res., 59: 803-806,  1999.

Andre C., Hampe A., Lachaume P., Martin E., Wang X. P., Manus V., Hu W. X., Galibert F. Sequence analysis of two genomic regions containing the KIT and the FMS receptor tyrosine kinase genes. Genomics, 39: 216-226,  1997.

Nocito A., Bubendorf L., Maria Tinner E., Suess K., Wagner U., Forster T., Kononen J., Fijan A., Bruderer J., Schmid U., Ackermann D., Maurer R., Alund G., Knonagel H., Rist M., Anabitarte M., Hering F., Hardmeier T., Schoenenberger A. J., Flury R., Jager P., Luc Fehr J., Schraml P., Moch H., Mihatsch M. J., Gasser T., Sauter G. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J. Pathol., 194: 349-357,  2001.

Hoos A., Stojadinovic A., Mastorides S., Urist M. J., Polsky D., Di Como C. J., Brennan M. F., Cordon-Cardo C. High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer (Phila.), 92: 869-874,  2001.

Hoos A., Stojadinovic A., Singh B., Dudas M. E., Leung D. H., Shaha A. R., Shah J. P., Brennan M. F., Cordon-Cardo C., Ghossein R. Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am. J. Pathol., 160: 175-183,  2002.

Moch H., Schraml P., Bubendorf L., Mirlacher M., Kononen J., Gasser T., Mihatsch M. J., Kallioniemi O. P., Sauter G. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am. J. Pathol., 154: 981-986,  1999.

Torhorst J., Bucher C., Kononen J., Haas P., Zuber M., Köchli O. R., Mross F., Dieterich H., Moch H., Mihatsch M., Kallioniemi O., Sauter G. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Pathol., 159: 2249-2256,  2001.

Barlund M., Forozan F., Kononen J., Bubendorf L., Chen Y., Bittner M. L., Torhorst J., Haas P., Bucher C., Sauter G., Kallioniemi O. P., Kallioniemi A. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl. Cancer Inst. (Bethesda), 92: 1252-1259,  2000.

Schraml P., Kononen J., Bubendorf L., Moch H., Bissig H., Nocito A., Mihatsch M., Kallioniemi O., Sauter G. Tissue microarrays for gene amplification surveys in many different tumor types. Clin. Cancer Res., 5: 1966-1975,  1999.

Hoos A., Urist M. J., Stojadinovic A., Mastorides S., Dudas M. E., Leung D. H., Kuo D., Brennan M. F., Lewis J. J., Cordon-Cardo C. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am. J. Pathol., 158: 1245-1251,  2001.

Mucci N. R., Akdas G., Manely S., Rubin M. A. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum. Pathol., 31: 406-414,  2000.

Rubin M. A., Dunn R., Strawderman M., Pienta K. J. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am. J. Surg. Pathol., 26: 312-319,  2002.

Sallinen S. L., Sallinen P. K., Haapasalo H. K., Helin H. J., Helen P. T., Schraml P., Kallioniemi O. P., Kononen J. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res., 60: 6617-6622,  2000.

Engellau J., Akerman M., Anderson H., Domanski H. A., Rambech E., Alvegard T. A., Nilbert M. Tissue microarray technique in soft tissue sarcoma: immunohistochemical Ki-67 expression in malignant fibrous histiocytoma. Appl. Immunohistochem. Mol. Morphol., 9: 358-363,  2001.

Hedvat C. V., Hegde A., Chaganti R. S., Chen B., Qin J., Filippa D. A., Nimer S. D., Teruya-Feldstein J. Application of tissue microarray technology to the study of non-Hodgkin’s and Hodgkin’s lymphoma. Hum. Pathol., 33: 968-974,  2002.

Camp R. L., Charette L. A., Rimm D. L. Validation of tissue microarray technology in breast carcinoma. Lab. Investig., 80: 1943-1949,  2000.

Fernebro E., Dictor M., Bendahl P. O., Ferno M., Nilbert M. Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch. Pathol. Lab. Med., 126: 702-705,  2002.

Ginestier C., Charafe-Jauffret E., Bertucci F., Eisinger F., Geneix J., Bechlian D., Conte N., Adelaide J., Toiron Y., Nguyen C., Viens P., Mozziconacci M. J., Houlgatte R., Birnbaum D., Jacquemier J. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am. J. Pathol., 161: 1223-1233,  2002.

Rassidakis G. Z., Jones D., Thomaides A., Sen F., Lai R., Cabanillas F., McDonnell T. J., Medeiros L. J. Apoptotic rate in peripheral T-cell lymphomas.A study using a tissue microarray with validation on full tissue sections. Am. J. Clin. Pathol., 118: 328-334,  2002.

Yosepovich A., Kopolovic J. [Tissue microarray technology—a new and powerful tool for the molecular profiling of tumors]. Harefuah, 141: 1039-1041, 1090, 2002.

Hendriks Y., Franken P., Dierssen J. W., De Leeuw W., Wijnen J., Dreef E., Tops C., Breuning M., Brocker-Vriends A., Vasen H., Fodde R., Morreau H. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am. J. Pathol., 162: 469-477,  2003.

Tzankov A., Zimpfer A., Lugli A., Krugmann J., Went P., Schraml P., Maurer R., Ascani S., Pileri S., Geley S., Dirnhofer S. High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin’s lymphoma indicates overexpression of cyclin E1. J. Pathol., 199: 201-207,  2003.

Sauter G., Mirlacher M. Tissue microarrays for predictive molecular pathology. J. Clin. Pathol., 55: 575-576,  2002.

Yajima T., Kanda T., Yoshiike K., Kitamura Y. Retroviral vector targeting human cells via c-Kit-stem cell factor interaction. Hum. Gene. Ther., 9: 779-787,  1998.

Yamasaki T., Shimazaki H., Aida S., Tamai S., Tamaki K., Hiraide H., Mochizuki H., Matsubara O. Primary small cell (oat cell) carcinoma of the breast: report of a case and review of the literature. Pathol. Int., 50: 914-918,  2000.

Hochhaus A., Kreil S., Corbin A., La Rosee P., Lahaye T., Berger U., Cross N. C., Linkesch W., Druker B. J., Hehlmann R., Gambacorti- Passerini C., Corneo G., D’Incalci M. Roots of clinical resistance to STI-571 cancer therapy. Science (Wash. DC), 293: 2163 2001.

Hornick J. L., Fletcher C. D. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am. J. Clin. Pathol., 117: 188-193,  2002.

Kantarjian H. M., Talpaz M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin. Oncol., 28: 9-18,  2001.

Holst V. A., Marshall C. E., Moskaluk C. A., Frierson H. F., Jr. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod. Pathol., 12: 956-960,  1999.

Jeng Y. M., Lin C. Y., Hsu H. C. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett., 154: 107-111,  2000.

Bokemeyer C., Kuczyk M. A., Dunn T., Serth J., Hartmann K., Jonasson J., Pietsch T., Jonas U., Schmoll H. J. Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours. J. Cancer Res. Clin. Oncol., 122: 301-306,  1996.

Heinrich M. C., Corless C., Blanke C. D., Demetri G. D., Joensuu H., von Mehren M., McGreevey L., Wait C., Griffith D., Chen C.-J., Haley A., Kiese B., Druker B., Roberts P. J., Eisenberg B., Singer S., Silberman S., Dimitrijevic S., Fletcher C. D., Fletcher J. KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc. Am. Soc. Oncol., 21: 2a 2002.